TARDBP and amyotrophic lateral sclerosis: Our findings deserve further research to validate this new mechanism of action of niclosamide in preclinical experiments, performing dose-response treatments and testing the drug in additional ALS models, besides FUS mice, recapitulating key pathologies and biological processes seen in sporadic ALS [3], as, for instance, the typical hallmark of TDP-43 mislocalization [62].